Evidence map›Paper›PMID 28516306›Full record

ArticleClinical & experimental metastasis2017

Peritoneal metastasis from pancreatic cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC).

Martin Graversen, Sönke Detlefsen, Jon Kroll Bjerregaard, Per Pfeiffer, Michael Bau Mortensen

2 registry-linked trialsAbstract read
PubMed Publisher
In one paragraph

Article in Clinical & experimental metastasis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 36 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 3 pooled it
8.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03210298 unknown statusnot on this map

Multicenter, International Online Documentation of Indications and Results of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC Und PITAC) for Treating Malignant Peritoneal and Pleural Diseases

Typeobservational_patient_registrySponsorSabine RhodeRan2016 to 2022Enrolled1,000ConditionsPeritoneum Cancer, Peritoneum Neoplasm, Pleural Cancer, Pleural EffusionArmsPIPAC
NCT05400681 unknown statusnot on this mapstarted 2020, after this paper: background citation

Pre- and Postoperative Incidence and Prognostic Implication of Positive Peritoneal Lavage and Circulating Tumor DNA in Patients With Pancreatic Cancer

Typeobservational_patient_registrySponsorSonke DetlefsenRan2020 to 2024Enrolled200ConditionsPancreatic Cancer, Pancreatic Adenocarcinoma
3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 3 syntheses or guidelines pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. PIPAC for Gastrointestinal Malignancies.Journal of clinical medicine · 2023
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Martin GraversenUpper GI and HPB Section, Department of Surgery, Odense Patient Explorative Network (OPEN), Odense University Hospital, J.B. Winsloews Vej 4, 5000, Odense, Denmark. martin.graversen@rsyd.dk.ORCID 0000-0001-5719-4916
Sönke DetlefsenDepartment of Pathology, Odense University Hospital, Odense, Denmark.
Jon Kroll BjerregaardDepartment of Oncology, Odense University Hospital, Odense, Denmark.
Per PfeifferDepartment of Oncology, Odense University Hospital, Odense, Denmark.
Michael Bau MortensenUpper GI and HPB Section, Department of Surgery, Odense Patient Explorative Network (OPEN), Odense University Hospital, J.B. Winsloews Vej 4, 5000, Odense, Denmark.
Odense University Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with peritoneal metastasis (PM) from pancreatic cancer have a short life expectancy. Systemic combination chemotherapy leads to a median overall survival of 7-8 months. Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) is a treatment alternative, where studies in patients with PM from ovarian, gastric and colorectal cancer show a high safety profile and interesting results. This case study report data on the PIPAC treatment in patients with PM from pancreatic cancer. In a standard laparoscopy, chemotherapeutics (cisplatin and doxorubicin) are nebulized within the peritoneal cavity. After 30 min, the chemotherapeutics are evacuated through a closed system. The PIPAC procedure is repeated every 4-6 weeks. Five patients with PM from pancreatic cancer were treated with a total of 16 PIPAC procedures. All patients received >1 PIPAC and were eligible for evaluation of histological regression. Four patients demonstrated histological regression, and one patient had stable disease. Three patients are still alive, and the median overall survival is 14 months (range 10-20) since the diagnosis of PM. The histological regression and survival figures in this pilot study suggest activity of PIPAC with low-dose cisplatin and doxorubicin in pretreated peritoneal metastasis of pancreatic origin. This should now be evaluated in prospective studies.

Indexed as

AerosolsAgedAntineoplastic Combined Chemotherapy ProtocolsCisplatinDeoxycytidineDrug Administration RoutesDrug Delivery SystemsFemaleGemcitabineHumansMaleMiddle AgedPancreatic NeoplasmsPeritoneal NeoplasmsPressureProspective StudiesAerosolsCisplatinDeoxycytidineGemcitabineAerosolCarcinomatosisHistological regressionIntraperitonealPalliativePeritoneum

Identifiers

PMID28516306
OpenAlexW2615552839

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.